New diabetes drug tested against standard treatment in major Real-World trial
NCT ID NCT07198932
Summary
This study aims to compare the effectiveness and safety of two diabetes medications, cofrogliptin and linagliptin, when added to insulin therapy. It will follow nearly 600 Chinese adults with type 2 diabetes whose blood sugar isn't well controlled on their current treatment. The research will track participants for 24 weeks to see which medication works better at lowering blood sugar levels and has fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital of Hebei University
Baoding, China
-
Beijing Luhe Hospital Affiliated to Capital Medical University
Beijing, China
-
Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
-
Shanghai Changzheng Hospital
Shanghai, China
-
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
-
Xi'an International Medical Center Hospital
Xi'an, China
-
the First Medical Center of Chinese PLA General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.